Compare PRSO & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | HSCS |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 15.8M |
| IPO Year | 2000 | 2022 |
| Metric | PRSO | HSCS |
|---|---|---|
| Price | $0.30 | $2.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 11.7M | 86.2K |
| Earning Date | 11-12-2026 | 12-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.23 | 50.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,573,000.00 | $4,319.00 |
| Revenue This Year | N/A | $295.93 |
| Revenue Next Year | $191.73 | $18,321.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $0.28 | $1.63 |
| 52 Week High | $2.10 | $5.25 |
| Indicator | PRSO | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 31.28 |
| Support Level | N/A | $1.80 |
| Resistance Level | $0.46 | $2.18 |
| Average True Range (ATR) | 0.04 | 0.33 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 10.38 | 1.27 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.